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Background
Sodium valproate is a widely prescribed broad-spectrum
antiepileptic drug. It shows high inter-individual variability
in pharmacokinetics and pharmacodynamics and has a
narrow therapeutic range [1]. We evaluated the effects of
polymorphic Uridine diphosphate glucuronosyltransferase
(UGT2B7) metabolizing enzyme on the pharmacokinetics
of sodium valproate in the patients with epilepsy who
showed toxicity to therapy.
Materials and methods
Genotype analysis of the patients was made with polymer-
ase chain–restriction fragment length polymorphism
(RFLP) with sequencing. Plasma drug concentrations were
measured with reversed phase high-performance liquid
chromatography (HPLC) and concentration–time data
were analyzed by using a non-compartmental approach.
Results
The results of this study suggested a significant genotypic
as well as allelic association with valproic acid toxicity for
UGT2B7 polymorphic enzymes. The elimination half-life
(t1/2=42.2 h) of valproic acid was longer and the clearance
rate (CL=947 ml/h) was lower in the poor metabolizers
group of UGT2B7 polymorphism who showed toxicity
than in the intermediate metabolizers group (t1/2 = 36.5 h,
CL = 1,042 ml/h) or the extensive metabolizers group
(t1/2 = 27. h, CL = 1,602 ml/h).
Conclusions
Our findings suggest that the UGT2B7 genetic poly-
morphism plays a significant role in the steady state con-
centration of valproic acid, and it thereby has an impact
on the toxicity of the valproic acid used in the patients
with epilepsy.
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